Streetbeat News

Analyst Ratings

EXPR

Telsey Advisory Group analyst Dana Telsey has reiterated a High Risk rating on Express, Inc. (NYSE:EXPR), raising the price target to $20 from $2. The company is expected to report 2Q23 results on September 6. The analyst expects Q2 EPS of ($11.11), adjusted for the reverse stock split, and a sales decline of 5.2% Y/Y to $441 million. The company is taking an aggressive approach to reduce costs with $80 million in savings in FY23, a $30 million workforce reduction, and gross margin efforts. However, the analyst maintains the High Risk rating due to the competitive retail environment and margin pressure.

Portfolio Pulse from Nabaparna Bhattacharya

August 31, 2023 | 5:54 pm

MESO

Mesoblast Ltd reported FY23 revenues of $7.5 million, missing the consensus of $7.97 million. The company reported a narrower EPS loss of $(0.11), beating the consensus of $(0.57). Cantor Fitzgerald reiterated the Overweight rating but lowered the price target from $23 to $17 due to a lower probability of success assumptions for MESO's pipeline assets. The analysts see a path forward for remestemcel-L, and Mesoblast's late-stage pipeline of cellular drugs for inflammatory diseases is underappreciated.

Portfolio Pulse from Vandana Singh

August 31, 2023 | 5:49 pm

NKE

A large bearish position has been taken on Nike (NYSE:NKE), as observed in the publicly available options history. The sentiment among these big-money traders is split between 45% bullish and 54% bearish. The whales have been targeting a price range from $97.5 to $175.0 for Nike over the last 3 months. Stifel has maintained their Buy rating on Nike, with a price target of $135.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:48 pm

T

A large investor has taken a bullish stance on AT&T (NYSE:T), with Benzinga's options scanner spotting 10 uncommon options trades for the company. The sentiment of these big-money traders is split 50% bullish and 50% bearish. Whales have been targeting a price range from $10.0 to $17.0 for AT&T over the last 3 months. Citigroup upgraded its action to Buy with a price target of $17, while Morgan Stanley downgraded its action to Equal-Weight with a price target of $20. RBC Capital maintained their Sector Perform rating on AT&T, with a price target of $14.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:48 pm

SCHW

A whale investor has taken a bullish stance on Charles Schwab (NYSE:SCHW), with 60% of the investors opening trades with bullish expectations and 40% with bearish. The whale has been targeting a price range from $40.0 to $67.5 for Charles Schwab over the last 3 months. The price of SCHW is currently down -0.54% at $59.46, and RSI indicators suggest that the stock may be approaching oversold. The next earnings are expected to be released in 46 days.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:48 pm

CIVI

BMO Capital Markets analyst Phillip Jungwirth initiated coverage on Civitas Resources Inc (NYSE:CIVI) with an Outperform rating and a price target of $95.00. The analyst expects the company's fundamentals to improve due to a more favorable operating environment and higher oil prices through 2025. The company's recent foray into the Permian basin is expected to boost asset quality and drive diversification. The analyst also expects CIVI's free cash flow to remain strong in 2024 and leverage to reduce following the Tap Rock and Hibernia acquisitions.

Portfolio Pulse from Lekha Gupta

August 31, 2023 | 5:48 pm

MLTX

SLRN

UCBJF

UCBJY

Needham has initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $76. The company's lead product, sonelokimab (SLK), is seen as a potential best-in-class treatment for chronic dermatological ailments, outperforming established biologics. The market opportunity for SLK is estimated at $30 billion, expected to grow to $40-$50 billion by the mid-2030s. Needham sees UCB SA's (OTC:UCBJY) (OTC:UCBJF) bimekizumab and izokibep by Acelyrin Inc (NASDAQ: SLRN) as the main competitors to SLK.

Portfolio Pulse from Vandana Singh

August 31, 2023 | 5:38 pm

BAC

Bank of America's (NYSE:BAC) short percent of float has fallen 25.96% since its last report, with 53.27 million shares sold short, which is 0.77% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Bank of America has less short interest as a percentage of float, with an average of 0.85%.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:30 pm

SNOW

Snowflake's (NYSE:SNOW) short percent of float has fallen 6.03% since its last report, with 10.79 million shares sold short, which is 3.43% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. Compared to its peers, Snowflake has less short interest as a percentage of float, with an average of 5.70%.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:30 pm

V

Wedbush analyst Moshe Katri reiterated Visa Inc (NYSE: V) with an Outperform and a $270 price target. Visa's U.S. Payments volume data suggests slight growth improvements month-to-month, with quarter-to-date in-line performance with the June quarter. Visa announced volume and transaction data for July and August 1-28, 2023, showing a 7% YOY growth in U.S. payments volume. Visa's shares traded higher by 0.13% at $246.54 on the last check Thursday.

Portfolio Pulse from Anusuya Lahiri

August 31, 2023 | 5:29 pm